Abstract As the effect of P-glycoprotein (P-gp) transport on antidepressant delivery has been extensively evaluated using in vitro cellular and in vivo rodent models, an increasing number of publications have addressed the effect of P-gp in limiting brain penetration of antidepressants and causing treatment-resistant depression in current clinical therapies. However, contradictory results have been observed in different systems. It is of vital importance to understand the potential for drug interactions related to P-gp at the blood-brain barrier (BBB), and whether coadministration of a P-gp inhibitor together with an antidepressant is a good clinical strategy for dosing of patients with treatment-resistant depression. In this review, the complicated construction of the BBB, the transport mechanisms for compounds that cross the BBB, and the basic characteristics of antidepressants are illustrated. Further, the reliability of different systems related to antidepressant brain delivery, including in vitro bidirectional transport cell lines, in vivo Mdr1 knockout mice, and chemical inhibition studies in rodents are analyzed, supporting a low possibility that P-gp affects currently marketed antidepressants when these results are extrapolated to the human BBB. These findings can also be applied to other central nervous system drugs.
Background
Depression is currently the fourth most serious global health problem, especially in the developed world [1] . Most antidepressants used in the clinic are small, lipophilic molecules that can readily cross endothelial cells via passive diffusion [2] . For a long time, passive diffusion has been viewed as a major mechanism for good penetration of antidepressants at the blood-brain barrier (BBB). In the last 20 years, with the availability of the P-glycoprotein (P-gp) knockout mouse model, numerous studies have been conducted in P-gp knockout versus wild-type mice and significant P-gp efflux of antidepressants has been observed, followed by an increasing number of publications that address the important role of P-gp expressed at the brain capillary endothelial cells on the efflux of most antidepressants at the BBB [3] . Thus, efflux of antidepressants by brain P-gp has been regarded as one important factor that potentially results in treatment-resistant depression [4] . A series of studies in rodents with chemical inhibition of P-gp were conducted based on the observation in the knockout model. However, contradictory results have been observed for in vitro bidirectional transport studies using P-gp over-expressing cell lines (MDCK-MDR1) for most antidepressants that have previously been reported to exhibit marked P-gp efflux at the BBB [5] . In addition, association studies of ABCB1 genetic variants and clinical response to antidepressants have shown equivocal results [6] .
P-gp is expressed in the intestine, liver, kidney, and brain, and plays a vital role in drug absorption, distribution, and excretion. Whether P-gp can affect the delivery of marketed antidepressants into the brain is of great importance. However, the present ambiguous observations about the effect of P-gp on antidepressant penetration into the brain may mislead clinical research and drug discovery. To understand the potential for drug interactions related to P-gp at the BBB, and whether coadministration of a P-gp inhibitor with an antidepressant is a good strategy for patients with treatmentresistant depression, it is important to consider the factors that influence the brain penetration and the reliability of the P-gp effect in vitro as well as in vivo. In addition, it is necessary to make a rational extrapolation of P-gp effects on antidepressants from preclinical studies to clinical treatment.
Further investigations are needed to clarify the P-gp effect on antidepressant brain penetration. Over the past 20 years, our laboratory has performed a series of cellular, animal, and human studies and predicted transporter effects, transporter-enzyme interplay, and potential drugdrug interaction in the intestine, liver, and, recently, the brain using the Biopharmaceutics Drug Disposition Classification System (BDDCS). In this review, we conducted an extensive literature search and reanalyzed the available in vitro and in vivo data related to P-gp effects and brain penetration of antidepressants to characterize the P-gp effect on the delivery of antidepressants into brain, as well as its relevance for treatment-resistant depression.
Antidepressants

Depression
Major depressive disorder (MDD) is a psychiatric disease characterized by depressed mood accompanied by feelings of irritability, low self-esteem, hopelessness, worthlessness, and guilt. Other symptoms of MDD include decreased ability to concentrate, changes in appetite, weight or sleep patterns, low energy, increased fatigue, and diminished interest or pleasure in normally enjoyable activities. A diagnosis of MDD will be made if a patient exhibits five or more of the symptoms listed above for at least 14 days [7] .
Depression is the most prevalent of mental disorders, causing retraction from social life and premature death [8] . Currently, diagnoses of depression are increasing and it is proposed that depression will be counted among the top three most important world health problems by 2020 [9] . Depression affects patients' quality of life and work, and leads to higher rates of many other chronic diseases.
Increased pharmaceutical investments and healthcare costs are related to depression treatment. Antidepressants are a class of medications used to treat depression or prevent it from occurring. According to the US Food and Drug Administration (FDA) website, almost 30 antidepressants are currently available on the market. They work to normalize levels of a group of chemicals in the brain known as neurotransmitters. Certain neurotransmitters, such as serotonin, norepinephrine, and dopamine, have been found to be involved in improving mood and emotion (http://www. fda.gov/consumer). Based on the effects of antidepressants on different neurotransmitters, these drugs are grouped into several different classes: monoamine oxidase inhibitors, tricyclic antidepressants, serotonin and norepinephrine reuptake inhibitors, and selective serotonin reuptake inhibitors [10] .
Treatment-Resistant Depression
As might be expected, since numerous antidepressants are available, only about 60-70 % of patients respond to their first prescribed antidepressant (http://www.fda.gov/ consumer). The remaining 30-40 % of patients do not achieve satisfactory sustained improvement with reasonable doses for a sufficient duration. Moreover, 10 % of patients will not achieve a clinically adequate response to any prescribed antidepressant, which is defined as treatment-resistant depression [11] . Though the mechanisms of action of antidepressants are not adequately understood, there are multiple therapeutic strategies for treatment-resistant depression, such as administration of high-dose antidepressants, combination of antidepressants with augmenting agents or other antidepressants, psychotherapy, electroconvulsive therapy, vagus nerve stimulation, repetitive transcranial magnetic stimulation, and psychosurgery with deep brain stimulation [12, 13] .
From a pharmacokinetic perspective, the inability to reach therapeutic concentrations may contribute to treatment-resistant depression. For example, maprotiline 75 mg was shown to be more effective than 37.5 mg during a 1-year study [14] , and plasma concentrations of nortriptyline between 80 and 120 ng/mL was more effective than 40-60 ng/mL over 3 years [15] . Potential explanations for lower concentrations in plasma and the brain include high expression levels of metabolic enzymes in patients, concurrent dosing of metabolic inducers [11] , and P-gp expression at the BBB [16] . The latter (P-gp expression) is addressed in further detail in Sects. 5.2-5.4.
Pharmacokinetics of Antidepressants
Though the various antidepressants exhibit different mechanisms of action, they share similar pharmacokinetic properties. After oral administration, all antidepressants are well-absorbed in the gut, although they differ in the extent of intestinal and hepatic first-pass metabolism, leading to different amounts of unchanged drug reaching the systemic circulation, i.e., different bioavailability. Antidepressants are extensively metabolized in the liver by the cytochrome P450 (CYP) enzymes and are mainly excreted as metabolites in the urine, with only a small portion of the dose excreted as unchanged drug. Most antidepressants have relatively long half-lives, with remarkably different values for each drug. The half-lives of venlafaxine, paroxetine, and citalopram are 5, 21, and 36 h, respectively. Fluoxetine has a half-life that ranges between 1 and 4 days and is eliminated much slower than other antidepressants [17] .
Several pharmacokinetic factors contribute to the high inter-subject variability of antidepressant plasma concentrations. Numerous studies show that all the antidepressants are CYP substrates, mostly mediated by CYP3A4, CYP2C19, and CYP2D6, which can exhibit genetic polymorphisms, thus yielding variable individual concentrations [18] . In addition, it is difficult to define a clear threshold for a therapeutic window within which therapeutically effective concentrations can be defined. The range of concentrations yielding an effective response may vary by 10-to 20-fold in different patients [19] .
Although only a few of the antidepressants are inhibitors of CYP isoforms at therapeutic concentrations, potential drug-drug interactions must be considered when inhibitors and inducers of CYPs are dosed concomitantly.
3 Blood-Brain Barrier (BBB)
Introduction
The BBB is an interface that protects the central nervous system (CNS) from potentially harmful chemicals and maintains a stable environment by preventing permeation of most molecules from the circulating blood into brain. This physical barrier is formed by brain capillary endothelial cells, together with perivascular elements that surround the endothelial cell layer, as well as tight junctions between the cerebral endothelial cells.
Cerebral endothelial cells that line the brain capillary system are different from the endothelial cells in the periphery of the body. They do not have fenestrations and exhibit more mitochondria, sparse pinocytic vesicular transport, and more extensive tight junctions between overlapping cells [20] , all of which can efficiently impede compounds from permeating through endothelial cells and entering into brain. Endothelial cells, combined with perivascular elements, are defined as a neurovascular unit and mainly consist of astrocyte end feet, pericytes, and neurons. It was reported that these three elements are responsible for the induction and maintenance of BBB properties, such as the formation of tight junctions, organization of endothelial cells into capillary-like structures, and the polarized expression of transporters in the endothelial membranes [21] . Neurons are also associated with active vascular recruitment and subsequent remodeling [20] .
Tight junctions are dynamic structures that act as a gatekeeper by selectively restricting paracellular diffusion of molecules into the brain. Tight junctions consist of three transmembrane proteins, namely claudin, occudin, and junction adhesion molecules, as well as membrane-associated cytoplasmic proteins such as zonula occludens (ZO)-1, ZO-2, ZO-3, cingulin, and others [22] .
The BBB is unique not only because of the existence of this physical barrier, but also because of the expression of a polarized efflux transport system and enzymatic degradation in endothelial cells.
Transport Mechanism of Molecules Across the BBB
Due to the impermeability of the CNS, it is a challenge for most molecules to gain access into the brain, although a number of molecules do transfer from the blood to brain. Several mechanisms are potentially involved in this process. First, simple passive diffusion, which comprises both transcellular and paracellular diffusion, is driven by a concentration gradient that moves molecules from higher concentrations to lower concentrations until equilibrium is reached. Generally, transcellular permeability is limited to small molecules that have a molecule weight \500 Da and have a combination of attributes of sufficient hydrophilicity, so that the molecule can be dissolved in water, and sufficient lipophilicity, to be soluble in the hydrophobic core of the lipid bilayer [23] . Gases such as oxygen (O 2 ) and carbon dioxide (CO 2 ) can also diffuse through membranes in this manner. Paracellular diffusion, expected to play a predominant role in the permeability of hydrophilic molecules, seldom occurs due to the tight junctions in the BBB.
The second mechanism is endocytosis, which is an energy-dependent process that could apply to larger molecules, including some large proteins (e.g., insulin, albumin, and ceruloplasmin). Cells absorb molecules by engulfing them via a variety of mechanisms, such as receptor-mediated endocytosis, e.g., transferrin [24] and insulin [25] , and adsorptive-mediated endocytosis [26, 27] .
Third is carrier-mediated transport, which is an approach that is associated with the movement of molecules across the cell membrane via specific membrane proteins. Based on their inward or outward transport characteristics, they are classified as carrier-mediated influx or carrier-mediated efflux, respectively. Carriermediated influx is a common route for the transport of small endogenous molecules (i.e., amino acids, nucleosides, and glucose) into the CNS [28, 29] . Drugs can also be delivered into the brain by endogenous transporters expressed at the luminal and abluminal membranes of the endothelial cells [26] , such as glucose transporter (Glut1), equilibrative nucleoside transporter (ENT), monocarboxylate transporter (MCT) [24] , as well as the proton-coupled organic action (H?/OC) antiporter [30] . Carrier-mediated efflux can preferentially transport molecules that are lipid soluble and amphiphilic out of endothelial cells against a concentration gradient by adenosine triphosphate (ATP) hydrolysis, utilizing transporters such as P-gp (ABCB1) and breast cancer resistance protein (BCRP; ABCG2).
There are also ion channels expressed on the brain endothelial membranes that allow the passage of water, and the sodium (Na ? ), potassium (K ? ), and chloride (Cl -) ions [23] . It is obvious that the BBB allows the passage of water, some gases, and essential nutrients by passive or active influx to maintain neural function. The BBB can also selectively prevent the entry of xenobiotics that may be neural toxins by active efflux via P-gp and BCRP. In this way, the BBB can provide protection for the CNS and maintain stable brain function.
Coexistence of Passive and Carrier-Mediated
Transport at the BBB For a long time, it has been believed that lipophilicity and molecular weight are determinants for a drug to cross the BBB. In 1980, Levin showed a good correlation between the ability of a drug to partition into the lipid bilayer portion of the cell monolayer and penetration of the drug across the BBB [31] . However, exceptions have been found in further research. For example, molecules that do not have the commensurate lipophilicity, such as D-glucose and L-amino acids, can also enter endothelial cells [32] . In contrast, some molecules that have high lipid solubility, such as cyclosporine (ciclosporin), do not show high permeation into the brain [33] . As various transporter systems have been identified and the transcellular routes of various CNS drugs have been explored, it has been recognized that the majority of drugs that do not exhibit the correlation with lipophilicity are substrates of transporters. Influx transporters expressed at the membranes of brain capillary endothelial cells can explain the high permeability of polar molecules across the BBB. The efflux transporters, especially P-gp, can also explain why highly lipophilic drugs have apparently poor BBB permeability. Thus, active transport can play a predominant role in affecting the delivery of drugs into the brain, and, as such, the contribution of both passive diffusion and active transport must be considered when evaluating the permeation of CNS drugs across the BBB.
Parameters to Evaluate Brain Penetration
Brain penetration can be evaluated by two parameters: the rate of brain uptake and the extent of brain exposure at steady state [34] .
The rate of brain uptake is determined by BBB permeability and is a direct measure of a compound's ability to penetrate into brain and is not influenced by metabolism, plasma protein binding, or non-specific brain binding [35, 36] . Several in silico, in vitro, and in situ methods have been used for the prediction of BBB permeability. In vitro methods include cell-based systems such as MDCK-MDR1 and brain endothelial cells, as well as non-cell-based highthroughput parallel artificial membrane permeation assay (PAMPA)-BBB methods. In situ brain perfusion is the most common assay utilized to determine BBB permeability.
The extent of brain exposure is defined as the ratio of brain concentration to plasma concentration at equilibrium (Eq. 1). Since most antidepressants are administered longterm, the extent of exposure may be more critical than the rate of penetration. The total brain to plasma concentration ratio (K p,brain ) was historically the most commonly used in vivo parameter. It is assumed that compounds with high K p,brain values have more brain penetration than compounds with low K p,brain values. But this parameter often shows a poor correlation with pharmacodynamic response. It is argued that the K p,brain values are affected by the extent of plasma protein and brain tissue binding [37, 38] .
where f u is a measure of the fraction of unbound drug in plasma or brain, C brain and C p are the total concentrations in brain and plasma, respectively, and C u is the unbound concentration in brain (C u,brain ) or plasma (C u,p ). From Eq. 1, we can see that a high K p,brain can be caused by low plasma binding, high non-specific brain tissue binding, or a high unbound brain to plasma (B/P) ratio, and may not necessarily yield high penetration of unbound drug into the brain. Conversely, low K p,brain compounds may have high unbound drug brain exposure.
According to the free drug hypothesis, unbound brain concentrations are the driving force for receptor binding and membrane permeation [34, 39] . It is only the unbound brain concentrations that can interact with CNS receptors and targets. Therefore, the unbound brain to plasma concentration ratio at steady state, which is defined as K p,uu,brain , is used today as the pharmacological entity that quantifies the extent of brain exposure. Values of K p,uu,brain significantly lower than 1 indicate CNS restriction by active efflux, brain metabolism, and gingival cervical fluid (GCF) or cerebrospinal fluid (CSF) bulk flow. In contrast, a value greater than 1 is consistent with enhanced CNS distribution [38] . However, there are relatively few publications that define the appropriate cut-off for expected CNS activity following clinically relevant doses. In 2007, Kalvass et al. [38] proposed a cut-off of 0.33, with K p,uu, brain values less than 0.33 indicating poor brain exposure, and reiterated this choice more recently [40] .
The measurement of K p,uu,brain in rodent species can be achieved by several different methods. Microdialysis in vivo is the only method that can measure the concentrations of unbound drug in brain interstitial fluid (C u,brain ISF ) directly with continuous sampling to provide concentration-time profiles of drug in the brain. However, this method is limited by the technical difficulties, requiring special equipment and expertise [41, 42] . Another method is based on K p,brain , where intravenous infusion or subcutaneous or intraperitoneal administration of drug into animals is often combined with blood and tissue sampling to first measure K p,brain . Then, equilibrium dialysis of brain homogenate [43] or brain slice uptake studies [44] are conducted to measure brain f u values. Unbound concentrations in brain and plasma were estimated by multiplying the total concentration by the f u ratios in the brain and plasma, respectively. However, neither of these two methods can apply to clinical human brain penetration evaluation.
In clinical studies, CSF concentrations have been widely used as a surrogate for brain interstitial fluid (ISF) concentrations. The concept that the CSF and ISF are functionally equivalent may be found in neuroscience textbooks [45] and has been perpetuated for many years. However, brain anatomy and physiology, as well as brain-penetrating basic vital dye studies, indicate that drug entry into the CSF across the choroid plexus is an entirely separate process from drug transport across the BBB [46, 47] . CSF is a fluid compartment in rapid equilibrium with the blood. Drug concentrations in the CSF are highly heterogeneous depending on being localized in the spinal cord or in the different ventricles. The way that molecules can distribute from the CSF compartment into brain parenchyma and the ISF is through ependymal surface diffusion. However, the diffusion rate is much slower than the rapid rate of bulk flow (convection) into blood. Limited by slow diffusion, the transport of drug from the CSF to brain tissue is slow. Since there is no general relationship between CSF and ISF concentrations, the use of CSF instead of ISF concentrations to evaluate BBB penetration has been questioned [48, 49] . Yet Fridén et al. [50] , who used CSF as a surrogate to measure drug brain exposure, found the K p,uu,CSF values for 33 of 39 drugs to be within threefold of K p,uu,brain , supporting the comparison of K p,uu,CSF for cross-species evaluation of human brain exposure. The caveat lies in that there is an over-prediction tendency for K p,uu,brain , especially for substrates of efflux transporters. This can be explained by the less efficient efflux function of efflux transporters in the CSF-brain barrier than in the BBB [50] .
Biopharmaceutics Drug Disposition
Classification System (BDDCS) Prediction of P-Glycoprotein (P-gp) Effect in the Brain
In 2005, Wu and Benet proposed the BDDCS [51] . Drugs were classified into four categories based on their extent of metabolism and solubility: Class 1 (high solubility, extensive metabolism, high membrane permeability rate), Class 2 (low solubility, extensive metabolism, high membrane permeability rate), Class 3 (high solubility, poor metabolism, low membrane permeability rate), and Class 4 (low solubility, poor metabolism, low membrane permeability rate). The BDDCS provides a useful tool in early drug discovery for predicting oral drug disposition, food effects on drug absorption, transporter effects on drug absorption, routes of elimination, and potentially clinically significant drug interactions that may arise in the intestine, liver, and brain [52] [53] [54] . After oral administration, drugs go through a series of complicated pharmacokinetic processes before unbound concentrations yield effects at the target site. For CNS drugs many other factors (aside from the BBB and P-gp) can affect drug delivery to the site of action and limit brain concentrations, namely uptake and efflux transporters in the intestine and liver and their interplay with metabolizing enzymes. Benet and colleagues have successfully predicted and observed transporter effects and related transporterenzyme interplay in the intestine and liver based on BDDCS classification [51] [52] [53] . Recently, we predicted the brain-penetrating (BBB?) potential (i.e., ability to elicit clinically relevant brain-related pharmacodynamics at approved doses) for orally administered drugs using the BDDCS and gained an accuracy of more than 90 %. In our predictions, we combined molecular properties with biological factors, taking into account passive permeability rate and the active transporter P-gp [54] . Here, we apply the BDDCS to the prediction of BBB? potential for orally administered antidepressant drugs.
Class 1 Compounds
For Class 1 compounds, which are highly soluble, highly permeable, and extensively metabolized, the passive permeability at concentrations unrestricted by solubility appears to overwhelm any potential transporter effects [51, 55] . In this situation, Class 1 compounds may be substrates of transporters in cellular systems, but transporter effects will be clinically insignificant in the gut, liver, or brain. For example, verapamil is shown to be a substrate of P-gp in the MDCK-MDR1 cellular system, but it exhibits no clinically significant P-gp transporter effects in the intestine, liver, and brain [56] .
In 2012, Broccatelli et al. investigated the brain penetration of orally administered drugs [54] . They identified 153 marketed drugs that met three criteria: (1) the effect of the drug in the brain was known and generally agreed upon; (2) the BDDCS class was known; and (3) published studies exist for the drugs, characterizing in vitro their status as P-gp substrates. Of the 153 drugs, 82 were BDDCS Class 1 drugs, of which 63 were BBB? and were not P-gp substrates. The remaining 19 show significant P-gp efflux as determined in vitro in MDCK-MDR1 cells, yet 18 of the 19 were known as BBB? drugs from clinical data. Broccatelli et al. [54] used a lower cut-off, i.e., K p,uu,brain C0.10, than Kalvass and colleagues [38, 40] . Broccatelli and coworkers were influenced by the previous work of Li et al. [57] , and others referenced by Li et al., who had utilized a K p,brain lower cut-off of C0.10. However, there appears to be no published testing of the appropriate cut-off for a large group of similarly acting drugs, as we are testing here for antidepressants. As noted subsequently, relatively few antidepressants exhibit K p,uu,brain levels between 0.10 and 0.33. The one outlier in the 19 P-gp substrates mentioned above, colchicine, had been classified by Benet et al. [58] as a BDDCS Class 1 drug, but we now believe that colchicine is predominantly eliminated in humans as unchanged drug in the bile and should be more properly listed as BDDCS Class 3.
Most of the current antidepressant drugs are BDDCS Class 1 drugs and are extensively metabolized in liver and intestine. Based on BDDCS predictions, even though they are P-gp substrates, there should be minimal transporter effects in gut and liver and they should be BBB?. In Broccatelli et al.'s study [54] , 19 BDDCS Class 1 antidepressants were studied, of which 16 are not P-gp substrates and three are P-gp substrates. Of course, all of the 19 antidepressants are BBB?, which correlates well with the BDDCS brain penetration prediction. Recently, Poirier et al. [59] investigated the permeability rates and efflux ratios of 76 CNS drugs in LLC-PK1 cells over-expressing P-gp. Of the 76 drugs, 65 exhibited efflux ratios lower than 2, while the remaining 11 drugs had efflux ratios higher than 2 and were thus considered to be P-gp substrates, yet all of these 11 P-gp substrates had sufficient brain penetration. Among these 11 drugs, eight are categorized as BDDCS Class 1, yielding a good fit with our prediction that BDDCS Class 1 drugs are not affected by P-gp efflux clinically, even if they are P-gp substrates using in vitro cell systems [59] .
Nonetheless, consideration should be taken when antidepressant drugs are dosed together with enzyme inhibitors or inducers, which can markedly change drug exposure.
Class 2 Compounds
For Class 2 compounds, the high permeability rate will grant drug molecules rapid access into the gut membrane and enterocytes by passive diffusion, making intestinal uptake transporter unimportant. However, due to the low solubility of Class 2 compounds, the low concentrations of drug entering enterocytes do not overwhelm (or saturate) the efflux transporters, as is observed for Class 1 compounds, making efflux transporter effects potentially important in the gut. Class 2 drugs have also been observed to be affected by both uptake and efflux transporters in the liver [60] and brain [61] . Thus, transporter-enzyme interplay will be of great importance for highly metabolized BDDCS Class 2 drugs that are substrates for drug-metabolizing enzymes and transporters in the gut, liver, and brain.
In the gut, drug is absorbed by passive processes into enterocytes, where it may be metabolized by drug-metabolizing enzymes. However, apical efflux transporters, such as P-gp, can pump drug back into the intestinal lumen where it may then re-enter enterocytes, thereby allowing repeated access to the enzymes in the enterocytes, preventing the intact drug molecule from entering the hepatic portal blood. The intestinal metabolism of a drug could be changed as a function of P-gp activity, without either inhibiting or inducing intestinal enzymes. In this way, enzymes and transporters work in a coordinated manner to prevent xenobiotics from reaching the systemic circulation.
Compared to efflux-transporter interplay in the intestine, where drug molecules enter the organ on the apical side and access the efflux transporter prior to the enzyme, the efflux transporter-enzyme interaction in the liver is reversed, since drug molecules enter the liver on the basolateral side, encountering the enzyme prior to being effluxed by P-gp into bile. In this situation, some substrates that permeate into hepatocytes will be metabolized, and more parent substrates will be pumped out by P-gp or other efflux transporters to the bile duct without diffusing back into hepatocytes because it is against a concentration gradient. Therefore, inhibition of hepatic drug efflux can increase the extent of hepatic metabolism of a Class 2 drug due to the increased access of the drug to the metabolizing enzymes. In contrast, inhibition of intestinal drug efflux can lead to decreased intestinal metabolism of the concomitant drug due to decreased access of the drug to the enzymes [62] , as proposed by our laboratory or due to increased concentrations, facilitated by a lack of transporter effects that could result in saturation of the metabolizing gut enzymes [33] .
In the brain, drug-metabolizing enzymes are expressed in endothelial cells and brain regions (e.g., cortex, cerebellum, basal ganglia, hippocampus, substantia nigra, medulla oblongata, pons) [63] , thereby allowing metabolism to occur in the brain. When efflux transporter-enzyme interplay occurs, similar to what occurs in the intestine, drug molecules penetrate into the BBB on the apical side and access the efflux transporter prior to enzymes. Efflux transporters expressed in the apical side may decrease the amount of substrates penetrating into brain endothelial cells, thus decreasing the amount of both parent drug and drug metabolites in the brain. Therefore, when drug efflux transporters are inhibited or knocked out, more drug molecules traverse into the brain, causing more metabolites to be formed in the brain, which is similar to greater metabolite formation in the liver when P-gp is inhibited. However, compared to hepatocytes, the endothelial brain cells do not have fenestrations and the tight junctions are more extensive, which can impede exit of hydrophilic metabolites from the brain, potentially causing accumulation even though the metabolites are not substrates of efflux transporters. The efflux transporter-enzyme interplay in intestine, liver, and brain for BDDCS Class 2 drugs is depicted in Fig. 1 .
In the study of Broccatelli et al. [54] , 40 drugs are categorized as Class 2 drugs. Among these 40 drugs, 14 are P-gp substrates as determined by in vitro bidirectional MDCK-MDR1 cell line studies, of which 11 are BBBdrugs. The remaining three drugs are BBB? drugs that can readily access the brain, which means that for Class 2 drugs, 78.6 % of P-gp substrates are BBB-. Of the remaining 26 drugs that are not P-gp substrates, four drugs are BBB-and 22 are BBB?. It is obvious that the P-gp efflux transporter in brain can have an effect on the drug disposition of Class 2 drugs and should be avoided for CNS drugs. Further examination of the outlier drugs of Broccatelli et al. [54] and Poirier et al. [59] in terms of K p,uu,brain measurements may be a useful study.
Three antidepressants were categorized as BDDCS Class 2 in the study of Broccatelli et al. [54] , as shown in Table 1 . For antidepressants that are BDDCS Class 2 compounds, efflux transporters in the gut, liver, and brain may affect brain concentrations and should be considered. Influx transporters may facilitate the penetration of antidepressants into brain. Consideration should also be given when these drugs are coadministered with enzyme inhibitors and inducers, since Class 2 drugs are highly metabolized. Transporter-enzyme interplay is important and coadministration of a P-gp and/or enzyme inhibitor can greatly change the systemic exposure of drugs, and thereby yield central effects for drugs with low K p,uu,brain that do not exhibit central effects under normal dosing conditions.
Class 3 and Class 4 Compounds
For Class 3 and Class 4 compounds, which are poorly permeable drugs, uptake transporters are important for intestinal absorption, hepatocyte uptake, and brain penetration. Once these drugs enter the enterocytes, hepatocytes, or brain endothelial cells, efflux transporter effects can also occur. That is, since the influx of Class 3 and Class 4 compounds will generally be rate limited by an uptake transporter, the counter effects of efflux transporters will not be saturated and can also be important. Our further analysis of Broccatelli et al.'s dataset shows that 73 % of the P-gp substrates in BDDCS Class 3 and Class 4 are BBB-(11 of the 15 P-gp substrates are BBB-). Since Class 3 and Class 4 compounds are poorly metabolized, metabolic interactions are not important. Uptake transporter, efflux transporter, and uptake-efflux transporter interplay are of major importance.
Currently, there are few if any antidepressant drugs that are Class 3 or Class 4 due to their low permeability rate and low penetration into brain. Targeting relevant brain and intestinal uptake transporters and avoiding efflux transporters in the brain and gut should be considered for Class 3 and Class 4 CNS drugs.
In Table 2 , we summarize how transporters and enzymes affect antidepressant drugs. This can also be applied to other CNS drugs. The transporter effects and transporter-enzyme interplay predictions are based on clinically relevant doses. In other words, minor differences may be observed in preclinical studies. For example, a BDDCS Class 1 drug may exhibit 'Class 2-like' results when the dosage in animals is markedly lower than the comparative human dose.
Reliability of Methods to Evaluate Brain
Penetration of Antidepressants
In Silico Models
The increasing need for high-throughput drug discovery enhances the popularity of in silico models of BBB permeation. Numerous in silico models have been developed and validated, in which molecular structure and brain exposure relationships have been investigated. Historically, CNS penetration assessment in most in silico models were derived from Log K p,brain [64] [65] [66] , or Log permeability-surface area coefficient (Log PS) datasets [67] . Log K p,brain reflects the total drug concentration in the brain, which is highly influenced by brain and plasma protein binding and may be unrelated to BBB transport and unbound brain exposure. Log PS was developed to evaluate the permeability of a drug across the brain capillary endothelium in terms of unbound concentration. However, it is a BBB transport rate parameter, which is of little pharmacological consequence for the long-term administration of antidepressants. Thus, for antidepressants, it appears that the proposed cutoff for K p,uu,brain of 0.1 by Brocatelli et al. [54] may be more appropriate when considering in silico BBB? predictions for humans. More recently, a structure-brain exposure relationships in silico model was developed in terms of K p,uu,brain , which was reported to be a more promising parameter related to brain penetration [50] .
In Table 1 , the predicted brain penetration of antidepressants was evaluated based on several in silico models. The actual brain penetration of antidepressants was listed based on our previous work [54] . All of the antidepressants in Table 1 are actual BBB? drugs. Molecular descriptors, including calculated LogP, molecular weight, hydrogen bond acceptor count, hydrogen bond donor count, and counts of oxygen and nitrogen, are used to predict brain penetration through in silico models.
According to rules recommended by Norinder and Haeberlein [66] and Lipinski's BBB rules of thumb [68] , which are derived from Log K p,brain , 95 and 82 % of the 22 antidepressants, respectively, listed in Table 1 are predicted to have good penetration.
Calculated K p,uu,brain based on the projections to latent structures (PLS) model [50] was also used to assess brain penetration. All 22 antidepressants exhibit K p,uu,brain values C0.1, with four-fluvoxamine, paroxetine, quetiapine, and trazodone-falling below 0.33. Results showed that all antidepressants listed are predicted to readily cross In 2012, Broccatelli et al. integrated BDDCS classification with in vitro P-gp efflux and in silico permeability data and created a decision tree to predict drug brain penetration [54] . The VolSurf? descriptor CACO2, which was generated from Caco-2 cell permeation studies, was used as a surrogate for in vitro passive permeability [69] . Based on Broccatelli et al.'s decision tree, all of the listed antidepressants are predicted to be BBB?.
In silico models offer the promise of rapid, relatively inexpensive characterizations. However, the disadvantage of in silico model predictions of brain penetration is that the experimental brain penetration values, such as Log K p,brain or K p,uu,brain are measured using different experimental procedures, many using different animals versus man. The variations between different experiments can affect the accuracy of the experimental data on which these models were established [70] . In addition, being derived only from molecular structural information, most in silico models do not take into account the biological factors that are responsible for brain penetration.
The Parallel Artificial Membrane Permeation
Assay (PAMPA)
The PAMPA system is a parallel artificial membrane devoid of carrier-mediated and paracellular processes and is used as a high-throughput in vitro model to assess membrane passive permeation. It was first introduced by Kansy et al. [71] and has been widely used in the pharmaceutical industry to predict intestinal absorption. In 2003, Di et al. developed a modified PAMPA assay to predict BBB penetration (PAMPA-BBB) [72] . The main difference between the PAMPA and PAMPA-BBB models is the lipid membrane. Compared to the membranes of PAMPA, which consists of 2 % (w/v) dioleoylphosphatidylcholine dissolved in dodecane, the membranes used in the PAMPA-BBB model contain a more complicated porcine brain extract, so as to better mimic the BBB. Mensch et al. confirmed that both the PAMPA-BBB model and the PAMPA model accurately identified compounds that are BBB? and those that are BBB- [73] . According to historical PAMPA data at Pfizer, compounds with PAMPA apparent permeability coefficient (P app ) [5 9 10 -6 cm/s exhibited good permeability across Caco-2 and MDCK biological cell membranes [74] . Di et al. based their criteria on PAMPA-BBB values and previously reported BBB permeation ranges. A PAMPA-BBB P app above 4 9 10 -6 cm/s was predicted to yield high BBB permeation, a P app under 2 9 10 -6 cm/s was predicted to yield low BBB permeation, and the permeation of compounds with a P app value between 2 and 4 9 10 -6 cm/s was uncertain [72] . The PAMPA permeability rates of antidepressants are listed in Table 3 [34, 72, 74, 75] . In this dataset, only sertraline, with a PAMPA-BBB P app of 2.8 9 10 -6 cm/s, is lower than the high permeability cutoff set by historical Pfizer data (5 9 10 -6 cm/s) [74] or Di and coworkers (4 9 10 -6 cm/s) [72] . Contradictory PAMPA P app values have been reported for fluoxetine. We followed Di et al.'s PAMPA-BBB data for fluoxetine and treated it as a high passive permeability compound. From this dataset, all antidepressants, except sertraline, exhibit high passive permeability in vitro and are predicted to be BBB?.
The PAMPA membrane is a physicochemical barrier, which can only predict drug passive diffusion into brain endothelial cells. However, antidepressants may also be affected by active influx or efflux transport or by drug metabolism, which could change the permeability rate in vivo. For example, a drug can have a high PAMPA permeability, but being a substrate of an efflux transporter can lead to poor penetration into brain. Conversely, a low PAMPA permeability could underestimate the permeation of a drug, which is a substrate of an influx transporter into brain. To some extent, it may be unwise to judge brain penetration only by PAMPA classification, particularly for BDDCS Class 2 drugs. More information regarding drug transport and metabolism is needed. An evaluation of PAMPA-BBB permeability of BDDCS Class 2 drugs that do not exhibit central effects could be illuminating.
In Vitro Transport Studies in the MDCK-MDR1 Cell Line
MDCK-MDR1 cells are widely used to study P-gp efflux by conducting a bidirectional transport assay and evaluating the efflux ratio [74, [76] [77] [78] 80] . Since only the compound crossing the cell monolayer is measured, transport is less influenced by non-specific binding than by membranebased P-gp assays such as the ATPase assay [74] . The MDCK-MDR1 cell system can also be used to predict passive BBB permeability. At high transepithelial electrical resistance, low paracellular permeability of the system would be expected to be able to accurately predict compounds with poor transcellular permeability. In Table 4 we list in vitro transport data for 23 antidepressants in cell systems over-expressing P-gp, of which 20 are BDDCS Class 1, and three are Class 2. For 18 of these antidepressants more than one efflux ratio has been reported [74, [76] [77] [78] [79] [80] [81] [82] . Our laboratory carried out an extensive literature search of 153 orally administered drugs and analyzed their efflux ratio values in MDCK-MDR1 cell lines [54] . We observed that 77 % of the efflux ratios were determined in MDCK-MDR1 cell lines derived from the Netherlands Cancer Institute (Borst cell line), while 23 % were determined in MDCK-MDR1 cell lines originating from the US National Institutes of Health (NIH cell line). Based on data from drugs studied in both cell lines, there was a 4.26-fold higher ratio for NIH cell line studies than for Borst cell line studies. Since an efflux ratio higher than 2 has been adopted to identify P-gp substrates for Borst cell lines [83] , we suggested using an 8.5 efflux ratio cut-off for the NIH cell line to define P-gp substrates. When more than one efflux ratio value was available for the same drug in the same derived cell systems, the cut-off was applied to the average of all the published values. If the efflux ratio value of both Borst and NIH cell lines were available for the same drug, and the results in these two cell lines are inconsistent, as found for citalopram, we adopted the assignment based on the Borst cell line data.
According to these criteria, the great majority (83 %) of antidepressants exhibit no or weak P-gp-mediated transport. More specifically, 16 of 20 BDDCS Class 1 antidepressants and all three BDDCS Class 2 antidepressants (trazodone, trimipramine, and citalopram) are not P-gp substrates. Both a high permeability rate and absence of P-gp efflux facilitate drug transport into the brain, yielding a potentially high probability to cross the BBB. Two of the four BDDCS Class 1 antidepressants (escitalopram, clomipramine, paroxetine, and sertraline) showing marked P-gp efflux in the MDCK-MDR1 cells gave inconsistent results in multiple studies: clomipramine (yes-Wager et al. [79] ; no-Mahar Doan et al. [78] ) and paroxetine (yes-Wager et al. [79] , no-Feng et al. [74] ). One of the three BDDCS Class 2 antidepressants, citalopram, exhibited inconsistent P-gp efflux in studies conducted in different MDCK-MDR1 cell lines (yes-NIH cell lines [76] , no-Borst cell lines [74, 79] ).
Although transport studies in the MDCK-MDR1 cell line have been widely used to predict a compound's delivery into brain, there are still limitations in this system. For example, the antidepressant sertraline, which is a P-gp substrate exhibiting a low permeability of 2.1 9 10 -6 cm/s in the MDCK-MDR1 cell line (Table 4) , yields an in vivo P-gp extraction ratio of 1.1 and a K p,uu,brain of 1.60 [5, 40] . BDDCS Biopharmaceutics Drug Disposition Classification System, PAMPA parallel artificial membrane permeation assay MDCK-MDR1 cells, which are derived from canine kidney epithelial cells, differ from cerebral endothelial cells in terms of membrane permeability and endogenous transporter expression. Lack of metabolic activity in this cell system can influence disposition of highly metabolized antidepressants, making accurate estimation difficult based only on in vitro cell line studies. Moreover, in addition to the rate of brain uptake, the extent of brain exposure is also important to evaluate, since antidepressants are administered long-term. Therefore, the combination of in vitro and in vivo experimental strategies is necessary.
In Vivo Mdr1 Knockout Mouse Model
Since 1994, knockout mice that lack of the expression of P-gp have been available [84] . Experiments based on this model can be treated as a complete inhibition of P-gp leading to enhanced understanding of P-gp function. The knockout mouse model has been used to evaluate the P-gp effect of many antidepressants. In these studies most samples were taken at a single timepoint. Brain and plasma concentrations at this timepoint were determined and compared in knockout versus wild-type mice to assess the effect of P-gp [3, [85] [86] [87] . Some studies collected samples at multiple timepoints and thus the area under the plasma concentration-time curve (AUC) was used [5, 88, 89] . Here we collect these data in two sets, either AUC or single timepoint concentrations, and evaluate the extent of brain penetration and the effect of P-gp in knockout versus wild-type mice.
In Table 5 , calculations show that the lack of P-gp yields a 23 ± 15 % increase in the plasma AUC for 12 studies of ten antidepressants [see knockout/wild-type (KO/WT) plasma]. Brain exposure is generally increased to a greater extent (108 ± 83 %) in knockout versus wildtype mice (KO/WT brain). To investigate how much the lack of P-gp contributes to the increase of brain exposure, brain AUC is normalized to plasma AUC (KO/WT B/P), yielding a 69 ± 66 % increase for the 12 studies. The effects of P-gp on brain penetration of CNS drugs in knockout mice relative to wild-type counterparts can be assessed by comparing the in vivo efflux ratio [38] , which is calculated as the ratio of K p,brain in knockout and wildtype rats. Based on Doran's criteria [5] , the in vivo efflux ratio was compared relative to a unity criterion of 2. An in vitro efflux ratio value higher than 2 indicates P-gp has a pronounced effect on a drug's brain penetration. Whereas Kalvass et al. use a criterion of 3 [38] , here, for the nine drugs investigated by Doran et al. [5] , only fluvoxamine (2.26) and paroxetine (2.13) exhibit ratios greater than 2. Liu et al. [89] reported a value of 3.21 for citalopram in knockout versus wild-type rats, in contrast to the 1.89 value of Doran et al. Uhr et al. [88] reported a ratio of 1.03 for amitriptyline, and 1.45 for nortriptyline, a value less than 2, which is consistent with Doran et al. [5] . These results suggest that the contribution of P-gp for most antidepressants is marginal at best.
The in vivo efflux ratio has been shown to correlate well with the in vitro efflux ratio. However, since brain penetration is determined by multiple factors such as clinical concentration, passive permeability, influx transporters, efflux transporters, f u values in brain and plasma, and metabolism, the in vivo efflux ratio may not provide accurate estimation of CNS distribution impairment [38] . Since K p,uu,brain is a key parameter that can be used to evaluate the extent of brain exposure and estimate pharmacologically relevant brain partition, by combining the f u values in mouse plasma and brain [90] [91] [92] [93] K p,uu,brain was calculated and compared in knockout versus wild-type mice in Table 5 . The comparison of K p,uu,brain between BDDCS Biopharmaceutics Drug Disposition Classification System, ER efflux ratio, N no, NIH National Institutes of Health, Papp apparent permeability coefficient, P-gp P-glycoprotein, Y yes knockout and wild-type rodents exhibits a similar result to that seen for B/P ratios. However, it is obvious that even in wild-type mice, where P-gp may be highly expressed in brain, the K p,uu,brain values of all antidepressants in the list are still higher than 0.1 and 0.33, ranging from 0.56 to 1.67.
As drugs with K p,uu,brain values greater than or equal to 0.33 [38, 40] and 0.1 [54] are assigned as BBB?, this indicates that all of the antidepressants listed in Table 5 can penetrate into mouse brain. In Table 6 , blood and brain samples in knockout mice were only taken at a single timepoint. In this situation, concentration, instead of AUC, is utilized to calculate the B/P ratio and evaluate the extent of brain penetration. For amitriptyline, doxepin, and mirtazapine, there was no significant change of the B/P value in knockout versus wildtype mice. For paroxetine, trimipramine, and venlafaxine, there were slight increases of B/P in knockout mice, but less than twofold. Only citalopram had a KO/WT B/P value higher than 2. Interestingly, metabolites had higher KO/ WT B/P values than the parent drugs; most of the metabolites (E-10 OH-AMI, Z-10 OH-AMI, E-10 OH-NOR, Z-OH-NOR) have KO/WT B/P values higher than 2 and reaching as high as 8. It was suggested that complete knockout of P-gp may result in changes of enzyme expression [81, 89] . Based on the fact that the major CYP enzymes that mediate the metabolism of amitriptyline, such as CYP1A2 and 2B6, are expressed in brain regions [110, 111] , amitriptyline metabolism in brain probably occurs. The high in vivo efflux ratio of metabolites in brain may be explained by the increase of brain peripheral metabolism enzymes in knockout versus wild-type mice, thus leading to more metabolites formed in brain. The more hydrophilic properties of metabolites, which are more characteristic of a lower passive permeability, lead to the metabolites having difficulty in penetrating into brain membrane, thus causing metabolites accumulation in the brain.
Since antidepressants are administered long-term, the extent of penetration and P-gp impairment in long-term animal studies may provide guidance for human clinical studies. In Table 6 , long-and short-term administration may be compared. For the four drugs investigated (amitriptyline, venlafaxine, mirtazapine, and citalopram), there is no significant difference in the KO/WT B/P ratios between long-term dosing and short-term administration. However, the amitriptyline metabolites (nortriptyline, E-10 OH-N02, 2-OH-NOR) are observed to have much higher KO/WT B/P ratios following long-term administration, which indicates that there is brain accumulation of some antidepressant metabolites following long-term treatment in knockout mice.
In this review, P-gp effects on antidepressant brain penetration in knockout models, which have been investigated previously, were reanalyzed by calculating KO/WT B/P ratio and K p,uu,brain . Sertraline (BDDCS Class 1) was identified as a P-gp substrate in the MDCK-MDR1 cell model and has a minor P-gp effect in the knockout model [with a KO/WT B/P value of 1.11 and K p,uu,brain value of 1.60 (Table 5) ]. Interestingly, fluvoxamine, which is reported not to be a P-gp substrate in MDCK-MDR1 cell lines in two out of three studies in Table 4 , has an observed KO/WT B/P value of 2.26, which indicates a marked P-gp impact. Paroxetine and citalopram show discrepancies of KO/WT B/P in different studies, as listed in Tables 5 and 6 . This could be caused by a functional change of endogenous factors in knockout compared to wild-type mice. Besides these, other antidepressants show minor KO/WT B/P ratio differences in knockout versus wild-type mice. Meanwhile, as shown in Tables 5  and 6 , all K p,uu,brain values obtained here are higher than 0.33 (and thus 0.1) for both knockout and wild-type mice, which implies that all antidepressants previously investigated in a knockout model have good penetration into mouse brain.
Limitations in the use of the P-gp knockout mice have been discussed. O'Brien et al. suggested that up-regulation of BCRP in the P-gp knockout mice may potentially affect drug distribution in the brain, since there is an overlap between P-gp and BCRP substrates [4] . Though the amount of BCRP mRNA in the brain microvessels of abcb1a(-/-) mice was reported to be increased threefold relative to wild-type animals [94] , no change of BCRP at the protein expression level was observed [95] . It has also been suggested that complete knockout of P-gp may result in changes in the expression of metabolic enzymes and thus antidepressants may be metabolized differently [88, 96, 97] . In these studies, plasma concentrations are compared between wild-type and knockout mice. However, no pronounced increases or decreases of plasma concentrations for the antidepressants in knockout versus wild-type mice have been reported. Therefore, changes of brain exposure caused by enzyme or other non-cerebral factors do not appear to be material.
In Vivo Rat Model with P-gp Inhibition
Chemical inhibition of P-gp in rats has been routinely used to predict the potential for drug-drug interactions related to human P-gp efflux at the BBB with the development of non-invasive positron emission topography (PET) imaging methods. Studies in rats with a P-gp inhibitor, rather than P-gp knockout mice, can provide a useful tool to investigate the role of efflux transporters in terms of drug brain penetration [98, 99] .
Several studies have been conducted in wild-type rats with antidepressants coadministered with P-gp inhibitors. Table 6 The extent of brain penetration evaluated in Mdr1 knockout versus wild-type mice using single timepoint measurements Clarke et al. examined the influence of inhibition of P-gp on the brain penetration of imipramine and its metabolite desipramine [100] . Rats were pretreated with verapamil 20 mg/kg as a P-gp inhibitor, followed by an intraperitoneal dose of imipramine 15 mg/kg, and diverse brain region samples were taken to examine P-gp effects in the brain. Our reanalysis of the studies in Table 7 showed that the presence of verapamil resulted in increased concentrations of imipramine and its metabolite desipramine both in the brain and in the plasma. However, increases of B/P in most brain regions are less than 2 for imipramine, except in the frontal cortex (2.13). Interestingly, in another experiment conducted by the same group, where imipramine was administered intravenously and animals were pretreated with the same dose of verapamil, a converse decrease of imipramine plasma concentrations was observed, indicating that the effect of verapamil is complicated in vivo [16] . Inhibition studies were also conducted with different doses of nortriptyline, using cyclosporine as an inhibitor (Table 7 ) [101] . A high dose of cyclosporine (200 mg/kg) did not change the nortriptyline B/P more than twofold following either intraperitoneal or oral dosing. When both nortriptyline and cyclosporine are given orally, the plasma and brain concentrations of nortriptyline decrease and the measured metabolite increase, as compared to when both the drug and the inhibitor are given intraperitoneally, suggesting a gut effect of cyclosporine, as we have shown previously [62] . However, only small changes are observed for the B/P P-gp inhibition to control ratios for nortriptyline, although following oral dosing of the parent drug and cyclosporine, the E-10-OH NT metabolite ratio in the brain did exceed 2, although only a small change was found following intraperitoneal dosing.
In the case of escitalopram, there was a region-dependent efflux inhibition in the presence of the inhibitor cyclosporine in different regions of brain. An intra-arterial dose of cyclosporine 25 mg/kg resulted in a remarkable increase of the B/P ratio both in prefrontal cortex (3.23-fold) and hippocampus (2.67-fold), although plasma concentrations were unchanged. The authors proposed that the increase in brain concentrations was due to the inhibition of P-gp at the BBB [82] .
K p,uu,brain of antidepressants was further evaluated in rats. Imipramine, desipramine, and nortriptyline show K p,uu,brain values in Table 7 much higher than 0.33 [except for intravenous imipramine dosing where dialysate samples from brain extracellular fluid (ECF) were taken], implying good penetration into the brain. In studies that utilized brain ECF, i.e., dialysate values in Table 7 , instead of the brain concentration to investigate the P-gp effect in the brain, K p,uu,brain of imipramine is lower than 0.1 both in the presence and absence of the P-gp inhibitor verapamil [16] .
The K p,uu,brain of escitalopram is also lower than 0.1 without pretreatment of cyclosporine, yet increases (but below 0.33) with P-gp inhibition [86] . These microdialysis studies [16, 81] suggest that for K p,uu,brain values determined by this method, the cut-off between BBB? and BBB-may be even lower than 0.1.
The wild-type rat model allows one to evaluate the interplay of various transporters and enzymes in one system. However, some P-gp inhibitors can also inhibit metabolic enzymes. For example, verapamil is an inhibitor of CYP3A and cyclosporine (20 lmol/L) can inhibit CYP2D6 activity by 30 %, as well as CYP3A. Since most marketed antidepressants are BDDCS Class 1 and 2 drugs, which are highly permeable and extensively metabolized, the specificity of P-gp inhibitors is of vital importance in evaluating the chemical inhibition studies in vivo in rats.
Extrapolation from Preclinical to Clinical
Species Differences Between Humans and Rodents
The inconsistent reports between in vitro MDCK-MDR1 and in vivo rodents has been noted [82] , with the potential reason claimed to be the species differences of P-gp transport activity between humans and rodents. However, based on the analysis of 3300 Pfizer compounds by Feng et al., the efflux ratio of human MDR1 correlated well with mouse Mdr1a using highly expressed MDCK cell lines, reflecting an extensive substrate overlap between humans and mice [74] . Differences in expression levels between species have also been cited. Evidence showed that the P-gp expression level in mouse brain microvessels [102] is 14.1 fmol/lg protein. By contrast, a 2.33-fold smaller level in human brain microvessels (6.06 fmol/lg protein) than that of Mdr1a in mice was observed [103] .
In terms of species differences, other factors related to brain penetration have also been investigated. According to Di et al., no species differences in the brain f u between human, mice, and rats were found [104] . However, crossspecies differences in the inhibitory effect of typical P-gp inhibitors have been reported both in vitro and in vivo, suggesting a careful extrapolation of animal data to human data should be made when predicting the potential human P-gp effect [105, 106] .
Does P-gp Efflux at the BBB Extrapolate to Poor
Human Brain Penetration?
Since some rodent studies report that P-gp limits access of various antidepressants into brain [85, 86] , there is a Table 7 The extent of brain penetration evaluated in vivo rat models with P-glycoprotein inhibition References
Brain Plasma B/P For imipramine microdialysis samples, plasma and dialysate AUC (ngÁmin/mL) were calculated to compare P-gp inhibition effect. For other samples, concentration in plasma (ng/mL) and brain (ng/g) were calculated c 6 mg/kg IV bolus and continuous 4 mg/kg/h infusion to achieve steady state at 2 h concern that P-gp may restrict the brain exposure of antidepressants in humans and contribute to the high clinical treatment failure rates [4, 16] . Furthermore, the associations between functional single nucleotide polymorphisms (SNPs) in ABCB1 and antidepressant plasma pharmacokinetics, treatment response, or side effects have been reported [6, 87, 107] , showing equivocal results. For example, for the identified P-gp substrate paroxetine, treatment response was found to be significantly associated with the ABCB1 G2677T/A SNP in studies conducted by Kato et al. [108] , but not in a second study [109] . For the P-gp non-substrate nortriptyline, postural hypotension was observed to be more significant in patients carrying the C3435T SNP, which was explained as resulting from a P-gp function decrease causing accumulation of parent drug and metabolite [110] . Various SNP analyses suggest that the relevance of SNPs in ABCB1 is controversial, and that the effects of P-gp SNPs have minimal impact on the brain penetration of antidepressants.
Here, in our extensive literature review and data collection, most antidepressants show insignificant P-gp efflux and good penetration at the BBB, with minimal changes in genetic knockout or chemical inhibition rodent studies, which is consistent with the observations in MDCK-MDR1 cell lines that most antidepressants are not P-gp substrates in bidirectional transport cell systems.
Some antidepressants yield conflicting P-gp effects between in vitro cell system and in vivo rodent studies. For fluvoxamine and citalopram, which were identified as non-P-gp substrates in cell systems (Table 4 ), significant efflux in knockouts (Tables 5, 6 ) was observed. This probably can be explained by the distinct P-gp expression levels in different systems [111] , causing dissimilar sensitivity in terms of P-gp efflux. Specifically, it was shown that the P-gp expression levels in Borst MDR1-MDCK cell lines [112] and mouse brain microvessels [102] are 1.91 and 14.1 fmol/lg protein, respectively; whereas in knockout mice, the P-gp expression level could be treated as zero. Another potential reason that should be considered is that the identification of P-gp substrates in the NIH cell line is based on an efflux ratio of 8.5, which was a roughly statistical cutoff based on 153 drugs and may cause inaccurate results. For example, the transport study of zidovudine conducted in the NIH MDCK-MDR1 cell line reported that the efflux could be inhibited by the P-gp inhibitor GG918, with the efflux ratio decreasing from 5.79 to 4.25 [113] . This study suggested that zidovudine was a P-gp substrate even though the efflux ratio was lower than 8.5 and the ratio change was minimal. Integrating the data from both in vitro cell lines and in vivo rodents probably suggests that the antidepressants fluvoxamine (BDDCS Class 1) and citalopram (BDDCS Class 2) are P-gp substrates.
For escitalopram and paroxetine (BDDCS Class 1), which were identified as P-gp substrates in in vitro cell systems (Table 4) , P-gp efflux in vivo rodents was observed [for paroxetine-yes in AUC measurements (Table 5) , no in the single timepoint study (Table 6) ; for escitalopram-yes in the intra-arterial inhibitor study (Table 7) ]. However, so far there is no direct evidence showing that efflux transporters could clinically prevent these drugs from penetration into the brain, thereby decreasing efficacy at the site of action.
In addition, from the data analysis above, we can see that no matter whether the transport of antidepressants are mediated by P-gp or not, all of them are BBB? in rodents, with all K p,uu,brain values higher than the BBB? cut-off value of 0.33 that was proposed by Kalvass and coworkers [38, 40] and of 0.1 that was proposed by Broccatelli et al. [54] . The only exception is the K p,uu,brain values obtained in microdialysis methods that possibly represent a methodological difference in brain penetration measurements. These findings are in accordance with our BDDCS prediction in terms of brain penetration that transporter effects will be clinically insignificant for BDDCS Class 1 drugs.
Preclinical P-gp Efflux Inhibition at the BBB:
An Effective Strategy for Human Therapy?
According to our observations above, most antidepressants are not P-gp substrates. Among the six antidepressants that may be P-gp substrates, five of them belong to BDDCS Class 1, which were validated to have a low chance of being affected by P-gp transport in the brain. We believe that P-gp efflux does not exert a significant impact on most antidepressants at the BBB, and that it is unrelated to treatment-resistant depression. However, for the BDDCS Class 2 antidepressant citalopram, which is probably a P-gp substrate, the P-gp transporter effect at BBB is complicated, with a greater chance of being affected. In this case, whether coadministration of a P-gp inhibitor with citalopram is a good strategy could be considered. There are studies suggesting that certain drugs including antidepressants can induce and inhibit P-gp, e.g., venlafaxine and sertraline, respectively. These data, as well as other potential effects of regulation of P-pg in depression, have been reviewed by O'Brien et al. [4] . Consistent with our general belief, these data do not convince us that P-gp exhibits clinically relevant effects on antidepressant activity.
Based on a study reported by Bart et al., there is a 770 % increase of verapamil B/P ratio in the Mdr1a/b knockout mice compared with wild-type mice [114] . In wild-type mice with cyclosporine 50 mg/kg as a P-gp inhibitor, the B/ P ratio of verapamil increased 5.3-fold [115] . In contrast, Sasongko et al. only observed a B/P ratio increase of 88 % in the presence of high-dose cyclosporine in a human PET study [56] .
It is difficult to extrapolate rodent data to evaluate the potential of clinical drug-drug interactions at the BBB in human clinical studies. Feng et al. recommended a B/ P AUC ratio cutoff of 4 between P-gp knockout and wildtype mice if one were to expect a P-gp effect in vivo at the BBB [74] . However, based on current clinical data, there are no consistent examples that inhibition of P-gp in the BBB results in higher brain concentrations, leading to adverse drug effects [96, 116] . The International Transporter Consortium noted that ''Despite the large increases in CNS exposure observed in animals and the clinical availability of very potent P-gp inhibitors, appreciable enhancement of CNS drug exposure as a result of P-gp inhibition has not been demonstrated in humans. The limited success in inhibiting BBB efflux is primarily explained by the inability to achieve unbound systemic inhibitor concentrations that are sufficient to elicit appreciable inhibition … Significant clinical DDIs at the BBB are thus not anticipated with currently marketed drugs under clinically relevant dosing conditions'' [116] . Therefore, the large differences observed in comparing rodents to humans can be explained by the inability to achieve inhibitor unbound plasma concentrations higher than inhibition constant (K i ) in humans but not in rodents [117] .
The relationship between the extent of efflux inhibition and increase in brain exposure can be depicted as Eq. 2: Fold CNS increase 100 % 100 % À inhibition % ð2Þ
Equation 2 shows that when a 50 % inhibition is achieved by a P-gp inhibitor, the increase of CNS exposure is twofold compared to the untreated group. However, most P-gp inhibitors cannot reach an unbound concentration higher than K i at conventional doses [116] . Based on this, for antidepressants with limited P-gp efflux at the BBB, it appears to us that coadministration of P-gp inhibitors together with citalopram to enhance brain penetration is not a reliable strategy.
Sufficient Brain Penetration: Incorporating Passive Permeability, P-gp Efflux and Unbound Fractions in the Brain and Blood
Some publications report that a high P-gp efflux ratio in an in vitro cell system is a reflection of a high P-gp efflux in vivo and low penetration of the compound into brain [40] . Although P-gp limits CNS penetration, it does not always preclude it entirely. We should take a balanced view on the roles of passive diffusion and active efflux in drug transport. Low passive permeability rate and high efflux ratio drugs are more likely to translate to poor CNS penetration, whereas high passive permeability rate and high efflux ratio drugs are likely to have good CNS penetration. One possible reason for this discrepancy between in vitro and in vivo studies is that passive transcellular transport could be rapid enough to overcome carrier-mediated efflux [118] . To our knowledge, the efflux ratio does not seem to be a strong predictor of in vivo CNS penetration. Supporting this hypothesis is a study conducted by Doran and colleagues [5] who have investigated the P-gp effects of 32 CNS drugs in Mdr1a/1b knockout mice and demonstrated that the impact of P-gp is minor for the majority of CNS drugs, although most of them demonstrated significantly greater B/P ratios in knockout mice than in wild-type mice. Using the CNS drug risperidone (BDDCS Class 1) as an example, they showed that risperidone is a good substrate of P-gp but it is still clinically effective [5] . By looking at the in vivo data collected in Tables 5, 6 and 7, some antidepressants are affected by P-gp in wildtype mice or rat, but they exhibit BBB? with K p,uu,brain values higher than 0.33. In addition, even when P-gp is knocked out or inhibited, K p,uu,brain values are not markedly increased. This indicates that P-gp efflux is not the only factor that impacts drug brain penetration.
In some situations, even low permeability rates and high efflux ratios may not translate into poor brain penetration. Based on a study of Summerfield et al., compounds (GSK2 and GSK3) that fell into these criteria exhibited in vivo unbound brain to blood concentration ratios of 0.5 and 1, respectively, thus highlighting the role of brain and plasma f u values in determining the CNS penetration [119] . f u values and non-specific tissue binding can act as compensating forces for the free drug.
Conclusions
Our investigation summarized the advantages and limitations of different models, and the consistency found in evaluating brain penetration among different models. The belief that antidepressants are substrates of P-gp and antidepressants treatment-resistant depression may be related to P-gp effects are based primarily on the results in P-gp knockout animals. Our re-analysis showed that only very few antidepressants are P-gp substrates in MDCK-MDR1 bidirectional transport models and most antidepressants have B/P ratios lower than 2 in P-gp knockout versus wild-type animals. In addition, these antidepressants exhibit high permeability in PAMPA and other cell systems, and the K p,uu,brain for the investigated antidepressants is greater than 0.1. Thus, even a high P-gp efflux ratio does not necessarily translate into poor brain penetration. The involvement of P-gp effect in BBB is more closely associated with poor permeability drugs. Consequently, there appears to be little possibility that treatment-resistant depression is due to the P-gp efflux liability for these antidepressants. Other factors, such as enzyme induction, may be considered since most antidepressants are BDDCS Class 1 and 2 drugs. This analysis could also be applied to other CNS drugs, such as antiepileptic drugs and antipsychotics, where drug resistance due to P-gp effects has been proposed.
